Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, explains for which infections ceftazidime-avibactam is approved by the US Food and Drug Administration.
Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, explains for which infections ceftazidime-avibactam is approved by the US Food and Drug Administration.
Interview Transcript (slightly modified for readability)
“[Ceftazidime-avibactam] is currently only FDA-approved for intra-abdominal infections and urinary tract infections; however, it seems like a lot of people are using it for a lot of other infections, more severe infections [like] bacteremias [and] pneumonias. I’ve seen posters at these infectious disease conferences [that imply that] people are using it in other infections, and I’ve personally used [ceftazidime-avibactam] in other infections.
So [this combination is] only approved for two infections in the US, but in Europe it’s actually approved for pneumonia, as of, I believe, summer [2016].”